Cybin Announces Additional U.S. Patent Supporting Its CYB003 Breakthrough Therapy Program In Phase 3 Development For Major Depressive Disorder
Refinitivقراءة أقل من دقيقة
Cybin Inc 
CYBN:
CYBIN ANNOUNCES ADDITIONAL U.S. PATENT SUPPORTING ITS CYB003 BREAKTHROUGH THERAPY PROGRAM IN PHASE 3 DEVELOPMENT FOR MAJOR DEPRESSIVE DISORDER
قم بتسجيل الدخول أو إنشاء حساب مجاني إلى الأبد لقراءة هذه الأخبار